The ongoing trial is testing the therapy – RBX2660 – as a treatment for Clostridioides difficile infection or C. diff, a bacterium that causes diarrhoea and inflammation in the colon and is a ...
The product is based on purified Firmicutes bacterial spores delivered in an oral capsule that is designed to encourage the regrowth of healthy bacteria after antibiotic treatment for C.
The study, published Sept. 30 in Open Forum Infectious Diseases, analyzed 45,049 patient records from 779 hospitals of adults who received treatment for C. diff infections before and after 2021.
The use of fidaxomicin for Clostridioides difficile infection (CDI) has increased significantly since 2021 but it remains underutilized, researchers reported today in Clinical Infectious Diseases.
WinMerge is an Open Source differencing and merging tool for Windows. WinMerge can compare both folders and files, presenting differences in a visual text format that is easy to understand and handle.